Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Preclinical symbols : SNYNF save search
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Published: 2024-04-10 (Crawled : 09:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
IPHA | $2.48 3.88% 8.1K
|
Health Technology
|
| O: -3.85%
H: 1.2%
C: 0.8%
iph45 pharma drug candidate antibody preclinical
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
Published: 2024-04-08 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
preclinical meeting
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
Published: 2024-03-12 (Crawled : 00:00) - prnewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -0.12%
H: 0.3%
C: -2.29%
preclinical meeting
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
Published: 2024-03-06 (Crawled : 11:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.0%
H: 0.8%
C: 0.8%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
IPHA | $2.48 3.88% 8.1K
|
Health Technology
|
| O: 0.78%
H: 1.93%
C: 0.97%
iph45 pharma drug antibody preclinical
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1449 -10.83% -12.15% 5M
|
Health Technology
|
| O: -3.69%
H: 4.0%
C: -0.58%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
tnx-1500 pharmaceuticals preclinical
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
Published: 2024-01-30 (Crawled : 12:00) - globenewswire.com
TSVT | $4.985 -1.09% -1.1% 390K
|
|
| O: 11.17%
H: 12.63%
C: 3.35%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.02%
H: 0.44%
C: 0.39%
cell acquisition preclinical
Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)
Published: 2023-10-17 (Crawled : 23:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
pharma conference association international research preclinical program
Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer
Published: 2023-08-08 (Crawled : 03:00) - prnewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 2.58%
H: 0.41%
C: -1.13%
ibi363 antibody cancer preclinical results
Apogee Files for IPO with Promising Preclinical Immuno Asset
Published: 2023-06-23 (Crawled : 14:20) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -2.99%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
preclinical
Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
Published: 2023-03-14 (Crawled : 23:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -1.13%
H: 0.0%
C: -0.22%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.68%
H: 0.55%
C: 0.42%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
preclinical meeting therapeutics cancer
Ajax Therapeutics Appoints Alan Collis, PhD, as Senior Vice President and Head of Preclinical Development
Published: 2023-03-09 (Crawled : 13:20) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.22%
H: 0.1%
C: -1.36%
preclinical therapeutics
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023
Published: 2023-03-08 (Crawled : 01:00) - prnewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
pharma global preclinical biotech
Global Pharma and Biotech Preclinical Stage Partnering Terms and Agreements Directory 2015-2022: Analysis of Preclinical Stage Deal Structure - Headline, Upfront, Milestone and Royalty Data
Published: 2022-12-19 (Crawled : 21:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: -1.72%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
pharma global preclinical biotech deal milestone
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone Everest Medicines announced that the company has achieved the preclinical proof-of-...
Published: 2022-12-15 (Crawled : 08:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
PRTA 4 | $21.99 -1.12% -1.14% 530K
|
Health Technology
|
| O: 0.97%
H: 7.04%
C: -0.02%
MTP | $0.4703 -70.79% -73.69% 0
|
Health Technology
|
| O: -4.03%
H: 2.0%
C: -15.78%
preclinical vaccine program mrna milestone
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
Published: 2022-06-02 (Crawled : 16:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -2.55%
H: 0.0%
C: -0.12%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.4%
H: 2.47%
C: 2.4%
system preclinical technology results publication pre-clinical
Elicio Touts "Huge Potential" for Cancer Vaccine Following Preclinical Data
Published: 2022-05-23 (Crawled : 14:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -3.11%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
preclinical vaccine cancer pre-clinical potential
Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting
Published: 2022-05-20 (Crawled : 12:00) - globenewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 10.05%
H: 0.07%
C: 0.07%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: 0.0%
KYMR | $34.4 -3.32% -3.43% 530K
|
Health Technology
|
| O: -2.71%
H: 2.3%
C: -3.02%
kt-474 preclinical skin therapeutics pre-clinical
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
Published: 2022-05-10 (Crawled : 12:00) - biospace.com/
RLYB | $1.83 -16.82% -20.22% 1.7M
|
|
| O: -7.81%
H: 9.95%
C: 5.32%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
preclinical antibody potential sanofi license pre-clinical
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation
Published: 2022-05-05 (Crawled : 19:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.98%
H: 0.0%
C: -2.72%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
KYMR | $34.4 -3.32% -3.43% 530K
|
Health Technology
|
| O: -0.73%
H: 0.55%
C: -8.5%
preclinical therapeutics results pre-clinical
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
Published: 2021-12-07 (Crawled : 09:00) - globenewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: -1.25%
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 3.63%
H: 0.0%
C: 0.0%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
XNCR | $20.09 -1.9% -1.94% 390K
|
Health Technology
|
| O: -2.12%
H: 4.74%
C: 2.8%
VIR | $8.55 -4.68% -4.91% 770K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
preclinical sars-cov-2 pre-clinical
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.